Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 22, 2020, reporting events occurring on December 18, 2020. Twist Bioscience Corporation (TWST) entered into a material definitive agreement to lease a new facility in Wilsonville, Oregon.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. It discloses specific financial terms related to a new lease agreement:
- Lease Term: 12 years, with options to extend by up to two additional five-year terms.
- Initial Annual Rent: Approximately $2.1 million (after partial rent abatement for the first year).
- Total Estimated Rent: Approximately $27.8 million over the initial term.
- Tenant Improvement Contribution: Landlord to contribute approximately $13.3 million.
- Letter of Credit: Company obligated to maintain approximately $1.0 million.
- Operating Expenses: Company obligated to pay 29.065% of applicable operating expenses and utilities.
Material Changes
The primary material change is the expansion of the Company's physical footprint. The Company secured approximately 110,995 square feet of space intended primarily as a second manufacturing facility. The lease commencement date is the later of August 16, 2021, or the date the Landlord substantially completes tenant improvements.
Outlook and Management Commentary
Management indicates the new premises will be used primarily for manufacturing, though permitted uses also include office, life science laboratory, research and development, and distribution. The agreement reflects a strategic commitment to scaling production capabilities.
Investor Verification Checklist
- Verify the exact "Commencement Date" once tenant improvements are completed.
- Confirm the impact of the $1.0 million letter of credit requirement on current liquidity.
- Review the full lease agreement (Exhibit 10.1) for specific definitions of operating expenses and utilities.
- Monitor the timeline for the $13.3 million tenant improvement contribution to ensure it aligns with capital expenditure plans.